Relationship between CD44 expression and differentiation of human prostate adenocarcinomas

Takahashi, Satoru; Kimoto, Naoya; Orita, Shin-ichiro; Chen, Lin; Sakakibara, Michihisa; Shirai, Tomoyuki

doi:10.1016/s0304-3835(98)00088-3

Cited by 12 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ekici et al found that CD44v6 expression was elevated in CaP patients who later had biochemical recurrence whereas Aaltomaa et al reported that CD44v6 is an independent predictor of survival of CaP patients. On the contrary, Noordzij et al reported that expression of CD44v6 is inversely correlated with prognosis of CaP patients treated by RP, and Takahashi et al found that CD44v6 has no correlation with CaP prognosis. In the current study, our findings support the idea that high levels of CD44v6 expression are associated with CaP progression and metastasis, which is conflicting with several previous studies where decreased level of CD44v6 was observed in primary CaP tissues, and even weaker presentation in lymph node metastasis.…”

Section: Discussionmentioning

confidence: 97%

“…On the contrary, Noordzij et al reported that expression of CD44v6 is inversely correlated with prognosis of CaP patients treated by RP, and Takahashi et al found that CD44v6 has no correlation with CaP prognosis. In the current study, our findings support the idea that high levels of CD44v6 expression are associated with CaP progression and metastasis, which is conflicting with several previous studies where decreased level of CD44v6 was observed in primary CaP tissues, and even weaker presentation in lymph node metastasis. The reasons for the conflicting results may be explained by the discrepancies in methodology such as experiment design, specimen selection, specificity of the antibodies, processing of the samples, patient population, different stages of samples chosen and the complexity of CaP itself.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 97%

CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The expression of CD44v6 is well known as a useful marker of tumor progression and prognosis in colorectal cancer (Yamane et al, 1999). A possible correlation between CD44 (sCD44 or CD44H) and differentiation of human prostate adenocarcinoma was observed (Takahashi et al, 1998). Soluble CD44 and variant isoform containing the v6 region were identified in cultured supernatants from all PC3 cell lines except LNCaP (Stevens et al, 1996).…”

mentioning

confidence: 96%

“…Expression of certain CD44 variant (v) isoforms in tumor cells has been correlated with metastatic and proliferative activities (Welsh et al, 1995). Immunohistochemistry studies demonstrated expression of sCD44 (68.1%), v6 (36.1%), and v9 (68.1%) to be relatively more frequent than other isoforms in prostate adenocarcinoma (Takahashi et al, 1998). In order to characterize the vCD44 isoforms expressed in PC3 cells, we performed RT-PCR analysis with the cDNA prepared from PC3 cells.…”

mentioning

confidence: 99%

Characterization of the expression of variant and standard CD44 in prostate cancer cells: Identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface

Desai

Zhu

et al. 2009

J of Cellular Biochemistry

View full text Add to dashboard Cite

CD44 is a glycosylated adhesion molecule and osteopontin is one of its ligand. CD44 undergoes alternative splicing to produce variant isoforms. Our recent studies have shown an increase in the surface expression of CD44 isoforms (sCD44 and v4-v10 variant CD44) in prostate cancer cells over-expressing osteopontin (PC3/OPN). Formation of CD44/MMP9 complex on the cell surface is indispensable for MMP9 activity. In this study, we have characterized the expression of variant CD44 using RT-PCR, surface labeling with NHS-biotin, and immunoblotting. Expression of variant CD44 encompassing v4-v10 and sCD44 at mRNA and protein levels are of the same levels in PC3 and PC3/OPN cells. However, an increase in the surface expression of v6, v10, and sCD44 in PC3/OPN cells suggest that OPN may be a ligand for these isoforms. We then proceeded to determine the role of sCD44 in MMP9 activation. Based on our previous studies in osteoclasts, we hypothesized that phosphorylation of CD44 has a role on its surface expression and subsequent activation of MMP9. We have prepared TAT-fused CD44 peptides comprising unphosphorylated and constitutively phosphorylated serine residues at positions Ser323 and Ser325. Transduction of phosphopeptides at Ser323 and Ser323/325 into PC3 cells reduced the surface levels of CD44, MMP9 activity, and cell migration; but had no effect on the membrane localization of MMP9. However, MMP9 knock-down PC3 cells showed reduced CD44 at cellular and surface levels. Thus we conclude that surface expression of CD44 and activation of MMP9 on the cell surface are interdependent.

show abstract

“…The ability of CD44 expression in biopsies and transurethral resections to predict tumor aggressiveness in prostatectomies had been evaluated [ 37 , 38 ], as had the association of biopsies and transurethral resections with anatomopathological factors and tumor progression [ 39 – 41 ]. Some authors have focused on primary tumors and metastases [ 10 , 42 – 45 ].…”

Section: Discussionmentioning

confidence: 99%

PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma

Hirth

Santos

Cerqueira

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Introduction CD44 has been proposed as a prognostic marker and a stem cell marker but studies in patients with prostate cancer have yielded inconsistent results. Patients and Methods Patients submitted to radical prostatectomy between 2008 and 2013 at a university hospital were followed with biannual serum PSA tests to determine the biochemical recurrence (BR). Archived paraffin blocks with neoplastic and nonneoplastic tissue were evaluated immunohistochemically for a panCD44 and MYC. Results Sixty-nine patients completed follow-up and were included. CD44 positivity was observed in inflammatory cells (42%), nonneoplastic epithelium (39.7%), and neoplastic tissue (12.3%). In nonneoplastic tissues staining was observed in basal and luminal cells with the morphology of terminally differentiated cells. In neoplastic tissues, CD44 negativity was correlated with higher Gleason scores (Rho = −0.204; p = 0.042) and higher preoperative serum PSA levels when evaluated continuously (p = 0.029). CD44 expression was not associated with tumor stage (p = 0.668), surgical margin status (p = 0.471), or BR (p = 0.346), nor was there any association between CD44 and MYC expression in neoplastic tissue (p = 1.0). Conclusion In the bulk of cells, the minority of cancer stem cells would not be detected by immunohistochemistry using panCD44. As a prognostic marker, its expression was weakly correlated with Gleason score and preoperative PSA level, but not with surgical margin status, tumor stage, or BR.

show abstract

Relationship between CD44 expression and differentiation of human prostate adenocarcinomas

Cited by 12 publications

References 17 publications

CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance

CD44 variant 6 is associated with prostate cancer metastasis and chemo‐/radioresistance

Characterization of the expression of variant and standard CD44 in prostate cancer cells: Identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface

PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma

Contact Info

Product

Resources

About